Healthcare - Medical - Diagnostics & Research - NASDAQ - US
$ 1.31
-1.5 %
$ 20.3 M
Market Cap
-1.44
P/E
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.[ Read More ]
The intrinsic value of one BIAF stock under the base case scenario is HIDDEN Compared to the current market price of 1.31 USD, bioAffinity Technologies, Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart BIAF
FINANCIALS
2.53 M
REVENUE
-7.97 M
OPERATING INCOME
-7.94 M
NET INCOME
-6.04 M
OPERATING CASH FLOW
-2.21 M
INVESTING CASH FLOW
-345 K
FINANCING CASH FLOW
2.35 M
REVENUE
-1.97 M
OPERATING INCOME
-2 M
NET INCOME
-1.71 M
OPERATING CASH FLOW
-9.41 K
INVESTING CASH FLOW
1.67 M
FINANCING CASH FLOW
Balance Sheet Decomposition
bioAffinity Technologies, Inc.
| Current Assets | 3.97 M |
| Cash & Short-Term Investments | 2.82 M |
| Receivables | 812 K |
| Other Current Assets | 340 K |
| Non-Current Assets | 4.25 M |
| Long-Term Investments | 0 |
| PP&E | 1.99 M |
| Other Non-Current Assets | 2.25 M |
| Current Liabilities | 2.25 M |
| Accounts Payable | 605 K |
| Short-Term Debt | 920 K |
| Other Current Liabilities | 723 K |
| Non-Current Liabilities | 1.12 M |
| Long-Term Debt | 1.12 M |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
bioAffinity Technologies, Inc.
| Revenue | 2.53 M |
| Cost Of Revenue | 1.74 M |
| Gross Profit | 792 K |
| Operating Expenses | 8.76 M |
| Operating Income | -7.97 M |
| Other Expenses | -36.2 K |
| Net Income | -7.94 M |
RATIOS
31.26%
GROSS MARGIN
-314.84%
OPERATING MARGIN
-313.41%
NET MARGIN
-163.47%
ROE
-96.54%
ROA
-150.40%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
bioAffinity Technologies, Inc.
| Net Income | -7.94 M |
| Depreciation & Amortization | 250 K |
| Capital Expenditures | -22.9 K |
| Stock-Based Compensation | 749 K |
| Change in Working Capital | 901 K |
| Others | 604 K |
| Free Cash Flow | -6.06 M |
Wall Street Analysts Price Targets
bioAffinity Technologies, Inc.
BIAF has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
bioAffinity Technologies, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
2 years ago
Aug 31, 2022
|
Bought 0 USD
|
KNIGHT PETER S
Director |
+ 8163
|
0 USD |
|
2 years ago
Aug 31, 2022
|
Bought 0 USD
|
KNIGHT PETER S
Director |
+ 8163
|
0 USD |
|
2 years ago
Aug 31, 2022
|
Bought 0 USD
|
Anderson Robert A.
Director |
+ 4081
|
0 USD |
|
2 years ago
Aug 31, 2022
|
Bought 0 USD
|
DIAMOND STUART
Director |
+ 4081
|
0 USD |
|
2 years ago
Sep 01, 2022
|
Bought 0 USD
|
Edwards James Michael
Chief Financial Officer |
+ 2448
|
0 USD |
|
2 years ago
Sep 01, 2022
|
Bought 0 USD
|
Edwards James Michael
Chief Financial Officer |
+ 2448
|
0 USD |
|
2 years ago
Aug 31, 2022
|
Bought 0 USD
|
Zannes Maria
President, CEO |
+ 16326
|
0 USD |
|
2 years ago
Aug 31, 2022
|
Bought 0 USD
|
Zannes Maria
President, CEO |
+ 16326
|
0 USD |
|
2 years ago
Aug 31, 2022
|
Bought 0 USD
|
GIRGENTI STEVEN
Executive Chairman |
+ 40916
|
0 USD |
|
2 years ago
Aug 31, 2022
|
Bought 0 USD
|
GIRGENTI STEVEN
Executive Chairman |
+ 40916
|
0 USD |
|
2 years ago
Sep 06, 2022
|
Bought 0 USD
|
GIRGENTI STEVEN
Executive Chairman |
+ 5952
|
0 USD |
|
2 years ago
Jul 20, 2022
|
Bought 0 USD
|
GIRGENTI STEVEN
Executive Chairman |
+ 2380
|
0 USD |
|
2 years ago
Aug 31, 2022
|
Bought 100 K USD
|
Rubin Gary D
director, 10 percent owner: |
+ 16326
|
6.125 USD |
|
2 years ago
Aug 31, 2022
|
Bought 0 USD
|
Rubin Gary D
Director |
+ 16326
|
0 USD |
|
2 years ago
Sep 06, 2022
|
Bought 2.5 M USD
|
Rubin Gary D
director, 10 percent owner: |
+ 408125
|
6.125 USD |
|
2 years ago
Sep 06, 2022
|
Bought 0 USD
|
Rubin Gary D
Director |
+ 408125
|
0 USD |
|
2 years ago
Jul 20, 2022
|
Bought 857 K USD
|
Rubin Gary D
director, 10 percent owner: |
+ 163248
|
5.25 USD |
|
2 years ago
Jul 20, 2022
|
Bought 0 USD
|
Rubin Gary D
Director |
+ 163248
|
0 USD |
|
2 years ago
Aug 31, 2022
|
Bought 120 K USD
|
Rubin Gary D
director, 10 percent owner: |
+ 16326
|
7.35 USD |
|
2 years ago
Aug 31, 2022
|
Bought 0 USD
|
Rubin Gary D
Director |
+ 16326
|
0 USD |
|
2 years ago
Aug 31, 2022
|
Bought 125 K USD
|
Rubin Gary D
director, 10 percent owner: |
+ 16326
|
7.656 USD |
7. News
bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies promotes Senior VP William Bauta, Ph.D., to Chief Science Officer to spearhead product development.
businesswire.com
- 1 week ago
WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement
JERSEY CITY, N.J. , Oct. 21, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, has closed its previously announced registered direct offering with institutional investors for the purchase and sale of 2,048,294 shares (the "Shares") of common stock at a price of $1.30 per share and concurrent private placement of common warrants (the "Warrants") to purchase up to 2,662,782 shares of common stock at an exercise price of $1.50 per common share for gross proceeds of $2,662,782 before deducting placement agent fees and other offering expenses payable by the Company.
prnewswire.com
- 3 weeks ago
bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces closing of $2.6 million registered direct offering and concurrent private placement.
businesswire.com
- 3 weeks ago
WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement
JERSEY CITY, N.J. , Oct. 18, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that– bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, has entered into a securities purchase agreement with institutional investors for the purchase and sale of 2,048,294 shares (the "Shares") of common stock in a registered direct offering at a price of $1.30 per share and, in a concurrent private placement, common warrants (the "Warrants") to purchase up to 2,662,782 shares of common stock at an exercise price of $1.50 per common share.
prnewswire.com
- 4 weeks ago
bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces pricing of $2.66 million registered direct offering and concurrent private placement.
businesswire.com
- 4 weeks ago
bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies' CyPath® Lung test will be added to the Federal Supply Schedule to help veterans and active military at risk for lung cancer.
businesswire.com
- 1 month ago
WallachBeth Capital Announces Closing of bioAffinity Technologies Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
JERSEY CITY, N.J. , Aug. 5, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that in connection with the BioAffinity Technologies (NASDAQ: BIAF) warrant exercise agreements dated August 2, 2024, with three existing accredited investors, such accredited investors have exercised outstanding warrants to purchase an aggregate of 1,041,667 of the Company's shares of common stock (the "Existing Warrants") at an exercise price that was reduced from $1.64 to $1.25 per share, for gross cash proceeds of approximately $1,302,083 and in consideration of such exercise, the exercising holders received in a private placement new unregistered warrants (the "New Warrants") to purchase up to an aggregate of 1,302,083 shares of common stock (equal to 125% of the shares of common stock issued in connection with the exercise of the Existing Warrants).
prnewswire.com
- 3 months ago
bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces closing of registered direct offering, private placement and warrant inducement for gross proceeds of $1.75 million.
businesswire.com
- 3 months ago
WallachBeth Capital Announces bioAffinity Technologies Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
JERSEY CITY, N.J. , Aug. 2, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ: BIAF) (the "Company") has entered into warrant exercise agreements with three existing accredited investors to exercise certain outstanding warrants to purchase an aggregate of 1,041,667 of the Company's shares of common stock (the "Existing Warrants").
prnewswire.com
- 3 months ago
Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / July 12, 2024 / RedChip Companies will air interviews with Biotricity, Inc. (Nasdaq:BTCY) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 13, at 7 p.m. Eastern Time (ET).
accesswire.com
- 4 months ago
BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / July 5, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 6, at 7 p.m. Eastern Time (ET).
accesswire.com
- 4 months ago
bioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath® Lung Tests
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports a 139% growth in the number of pulmonology practices and physicians ordering CyPath Lung for their patients.
businesswire.com
- 5 months ago
8. Profile Summary
bioAffinity Technologies, Inc. BIAF
COUNTRY
US
INDUSTRY
Medical - Diagnostics & Research
MARKET CAP
$ 20.3 M
Dividend Yield
0.00%
Description
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
Contact
22211 West Interstate 10, San Antonio, TX, 78257
https://www.bioaffinitytech.com
IPO Date
Sept. 1, 2022
Employees
75
Officers
Ms. Julie Anne Overton
Director of Communications
Mr. Xavier T. Reveles M.S.
Chief Operating Officer
Mr. Timothy P. Zannes J.D.
Executive Vice President, Secretary & General Counsel
Ms. Maria Zannes J.D.
Founder, President, Chief Executive Officer & Director
Mr. Steven Girgenti
Founder & Executive Chairman of the Board
Mr. Dallas J. Coleman
Vice President of sales
Mr. J. Michael Edwards CPA, M.B.A.
Chief Financial Officer & Principal Accounting Officer
Dr. William Bauta Ph.D.
Chief Science Officer